- Raised $7M funding round led by Axil Capital, Mar 2021
- Raised $2.5M grant, Jan 2024
- Raised $2.6M funding round led by Johnson & Johnson Innovation, May 2019
About
Techsomed leverages generative AI to transform ablation therapy, a minimally invasive technique for treating tumors, heart arrhythmias, and chronic pain. The company’s first offering, the BioTraceIO360 software suite, focuses primarily on liver tumor ablation procedures. Leveraging standard medical imaging modalities such as Ultrasound, CT, and MRI, Techsomed empowers physicians with tissue damage prediction, advanced patient-specific treatment planning, and interactive ablation procedure analysis.
Techsomed secured FDA De-Novo clearance for its post-ablation tissue response prediction offering, positioning BioTrace as the first and only FDA-cleared solution of its kind. Complemented by a 510K clearance for ablation treatment planning and confirmation, these flagship products lay the foundation for the comprehensive BioTraceIO360 Solution.
Operating globally, Techsomed maintains a subsidiary in Germany, housing an advanced R&D center—a spin-off from Fraunhofer, a leading German research institution specializing in imaging software solutions. Additionally, a subsidiary in Japan supports commercialization efforts in the Japanese and other Asian markets.
Funding history · 6 rounds · $12.9M total
Q&A
- What is Techsomed's primary focus?
- Techsomed specializes in ultrasound-based real-time monitoring systems for thermal ablation, leveraging generative AI to enhance ablation therapy for conditions like tumors, heart arrhythmias, and chronic pain.
- What is Techsomed's flagship product?
- Techsomed's flagship product is the BioTraceIO360 software suite, which focuses on liver tumor ablation procedures by providing tissue damage prediction, patient-specific treatment planning, and interactive ablation procedure analysis using standard medical imaging.
- Has Techsomed received any regulatory clearances for its products?
- Yes, Techsomed secured FDA De-Novo clearance for its post-ablation tissue response prediction offering, BioTrace, making it the first and only FDA-cleared solution of its kind. It also has a 510K clearance for ablation treatment planning and confirmation.
- Where are Techsomed's main operational centers located?
- Techsomed operates globally with its headquarters in Rehovot, Israel. It also maintains a subsidiary in Germany with an advanced R&D center and a subsidiary in Japan to support commercialization in Asian markets.
- When was Techsomed founded?
- Techsomed was founded in August 2012.
- How many employees does Techsomed have?
- Techsomed has 11-50 employees.
- What is Techsomed's total funding raised to date?
- Techsomed has raised a total of $12.9 million USD.
- When was Techsomed's most recent funding round?
- Techsomed's most recent funding round was a Grant in January 2024, with funding from the Israel Innovation Authority.
- Which investors participated in Techsomed's March 2021 funding round?
- The March 2021 funding round was led by Axil Capital, with participation from.
- Who is the CEO of Techsomed?
- Yossi Abu is the Founder & CEO of Techsomed.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | techsomed.com |
|---|---|
| linkedin.com/company/8141297 |
Identifiers & details
| Founded | 2012-8 |
|---|---|
| Employees (exact) | 29 |
Radar intelligence
Patents
| EPO | 3 |
|---|
Publications (Crossref)
| Works | 1 |
|---|
Web history (Wayback)
| Domain | techsomed.com |
|---|
Certificate / subdomain footprint
| Subdomains | 8 |
|---|